Cargando…

Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6

Although the SARS-CoV-2 Omicron variant (BA.1) spread rapidly across the world and effectively evaded immune responses, its viral fitness in cell and animal models was reduced. The precise nature of this attenuation remains unknown as generating replication-competent viral genomes is challenging bec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taha, Taha Y., Chen, Irene P., Hayashi, Jennifer M., Tabata, Takako, Walcott, Keith, Kimmerly, Gabriella R., Syed, Abdullah M., Ciling, Alison, Suryawanshi, Rahul K., Martin, Hannah S., Bach, Bryan H., Tsou, Chia-Lin, Montano, Mauricio, Khalid, Mir M., Sreekumar, Bharath K., Renuka Kumar, G., Wyman, Stacia, Doudna, Jennifer A., Ott, Melanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120482/ https://www.ncbi.nlm.nih.gov/pubmed/37085489 http://dx.doi.org/10.1038/s41467-023-37787-0

Ejemplares similares

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
por: Syed, Abdullah M., et al.
Publicado: (2022)

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
por: Syed, Abdullah M., et al.
Publicado: (2022)

Rapid assessment of SARS-CoV-2–evolved variants using virus-like particles
por: Syed, Abdullah M., et al.
Publicado: (2021)

A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo
por: Taha, Taha Y., et al.
Publicado: (2023)

A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo
por: Taha, Taha Y., et al.
Publicado: (2023)

Taking cues from convalescence to improve vaccines against hepatitis C virus
por: Sreekumar, Bharath K., et al.
Publicado: (2022)

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
por: Servellita, Venice, et al.
Publicado: (2022)

Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
por: Suryawanshi, Rahul K., et al.
Publicado: (2022)

Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination
por: Suryawanshi, Rahul K., et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Post-acute immunological and behavioral sequelae in mice after Omicron infection
por: Ma, Tongcui, et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines
por: Bowen, John E., et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
por: Kimura, Izumi, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
por: Wang, Qian, et al.
Publicado: (2022)

Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients
por: Pedersen, Rune M., et al.
Publicado: (2022)

Performance of rapid antigen tests in identifying Omicron BA.4 and BA.5 infections in South Africa
por: Samsunder, Natasha, et al.
Publicado: (2023)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
por: Torres, Carolina, et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
por: Kang, Sung-Woon, et al.
Publicado: (2023)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation
por: Dolliver, Stacia M., et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador
por: Carrazco-Montalvo, Andrés, et al.
Publicado: (2022)

Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients
por: Ferreira, Victor H., et al.
Publicado: (2023)

Modelling the impact of the Omicron BA.5 subvariant in New Zealand
por: Lustig, Audrey, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g4srb71413ssdt2pifa59m8vo9